The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment.
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
D'Amico, Emanuele;Zanghì, Aurora;Zappia, Mario;Patti, Francesco
2018-01-01
Abstract
The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Ther. Adv. Neurol. Dis. 2018.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
698.68 kB
Formato
Adobe PDF
|
698.68 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
